Biotechnology
Price
$528.04
+6.03%Market Cap
$115.02B
Day High
$529.14
Day Low
$501.53
Vertex Pharmaceuticals delivered a strong Q1 FY2026 with revenue of $2.99B (+7.8% YoY), operating income surging 80.6% to $1.14B, and net income jumping 59.6% to $1.03B, reflecting significant margin expansion and robust cash generation.
Key risk: Concentration Risk in Cystic Fibrosis Franchise
Vertex's revenue remains heavily dependent on its CF drug portfolio. Any competitive entry, label changes, reimbursement challenges, or safety issues affecting CF medicines could materially impact revenues. The 7.8% revenue growth, while solid, may reflect maturing CF market penetration in some geographies.
Other Biotechnology companies